Maurice Markus, MD, PhD


Medical Oncologist / Hematologist

Colorado Springs Style Magazine Top Doc 2017
Colorado Springs Style Magazine Top Doc 2018
Colorado Springs Style Magazine Top Doc 2019
Colorado Springs Style Magazine Top Doc 2020
Colorado Springs Style Magazine Top Doc 2021
Colorado Springs Style Magazine Top Doc 2022
Maurice Markus, MD, PhD | Oncologist at Rocky Mountain Cancer Centers

Colorado Springs - Penrose Pavilion

2312 N. Nevada Ave., Ste. 400
Colorado Springs, CO 80907

719-577-2555

Request an Appointment

About Maurice Markus, MD, PhD

Dr. Maurice Markus is a board-certified medical oncologist and hematologist. He joined the Colorado Springs location of Rocky Mountain Cancer Centers in 2007. Dr. Markus has a strong interest in genitourinary cancers. A collaborative approach to care is important to Dr. Markus’s practice strategy. He is active on multiple tumor boards, working closely with pathologists, radiologists, surgeons, radiation oncologists, and other subspecialties. In presenting and consulting on cancer cases, Dr. Markus can ensure his patients have the benefit of shared knowledge from multiple experts in planning their cancer treatment options. He has a true passion for treating his patients with compassion and understanding. He strives to provide evidence-based, cutting-edge treatment options to his patients.

Advanced Practice Providers Working With Dr. Markus

Board Certifications

Hematology
Internal Medicine
Medical Oncology

Specialties

  • Genitourinary Cancers
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
    • Testicular Cancer

Education

Fellowship

Duke University Medical Center, Durham, NC

Residency

New York-Presbyterian Hospital, New York, NY

Medical School

Weill Medical College of Cornell University, New York, NY

Patient Care Philosophy

It is important to integrate research advances into the care of patients. Oncology is a rapidly evolving discipline. Novel approaches to the diagnosis and management of cancer have resulted in remarkable improvements in the last several years. Malignancies for which there had been no good treatments and dismal prognoses can now often be rendered chronic and sometimes cured. I feel that patients should have access to state-of-the-art treatments and have access to clinical trials that may offer even better outcomes.

Additional Information

Alpha Omega Alpha Honor Medical Society
American Medial Association
American Society of Clinical Oncology
American Society of Hematology